Results 21 to 30 of about 5,151 (200)

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. [PDF]

, 2002
In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g x kg(-1) x wk(-1) or to a control group receiving epoetin alfa at an initial dose of 150 U x kg(-1) three times weekly.
Armstrong, S, Colowick, AB, Glaspy, JA, Jadeja, JS, Justice, G, Kessler, J, O'Byrne, J, Richards, D, Rossi, G, Schwartzberg, L, Tchekmedyian, NS   +10 more
core   +2 more sources

Randomized Study of Darbepoetin Alfa and Recombinant Human Erythropoietin for Treatment of Renal Anemia in Chronic Renal Failure Patients Receiving Peritoneal Dialysis

Journal of the Formosan Medical Association, 2008
Darbepoetin alfa can be administered less frequently than recombinant human erythropoietin (r-HuEPO) for the treatment of anemia in chronic renal failure (CRF) patients.
Wen-Yi Li, Tzong-Shinn Chu, Jenq-Wen Huang, Ming-Shiou Wu, Kwan-Dun Wu   +4 more
doaj   +1 more source

Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy. [PDF]

PLoS ONE, 2010
BackgroundErythropoiesis stimulating agents (ESAs) are widely used to treat anaemia but concerns exist about their potential to promote pathological angiogenesis in some clinical scenarios.
Carmel M McVicar, Liza M Colhoun, Jodie L Abrahams, Claire L Kitson, Ross Hamilton, Reinhold J Medina, Dash Durga, Tom A Gardiner, Pauline M Rudd, Alan W Stitt   +9 more
doaj   +1 more source

Cloning and expression of codon-optimized recombinant darbepoetin alfa in Leishmania tarentolae T7-TR [PDF]

, 2016
Darbepoetin alfa is an engineered and hyperglycosylated analog of recombinant human erythropoietin (EPO) which is used as a drug in treating anemia in patients with chronic kidney failure and cancer.
Fard-Esfahani, P., Golavar, R., Khajeniazi, S., Kianmehr, A., Mahrooz, A., Mostafavi, S.S., Oladnabi, M., Omidinia, E., Rouintan, M.   +8 more
core   +1 more source

Purification and Characterization of Recombinant Darbepoetin Alfa from Leishmania tarentolae [PDF]

, 2016
Darbepoetin alfa is a biopharmaceutical glycoprotein that stimulates erythropoiesis and is used to treat anemia, which associated with renal failure and cancer chemotherapy.
Ansari, J., Evazalipour, M., Kianmehr, A., Mahrooz, A., Oladnabi, M., Omidinia, E., Safdari, Y., Shahbazmohammadi, H., Veisi, K.   +8 more
core   +1 more source

Comparative efficacy and safety of biosimilar darbepoetin alfa in adults with anemia of chronic kidney disease

Indian Journal of Transplantation, 2018
Introduction: The present study compared the efficacy, safety, and immunogenicity of the biosimilar darbepoetin alfa to the reference innovator darbepoetin alfa in the treatment of anemia in chronic kidney disease (CKD) patients.
Prasad Apsangikar, Sunil Chaudhry, Manoj Naik, Shashank Deoghare, Jamila Joseph   +4 more
doaj   +1 more source

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer : randomized clinical trial [PDF]

, 2013
BACKGROUND: The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled epirubicin ...
Bois, Andreas du, Hinke, Axel, Huober, Jens, Jackisch, Christian, Kreienberg, Rolf, Kuhn, Walther, Kurbacher, Christian, Lueck, Hans-Joachim, Moebus, Volker, Nitz, Ulrike, Runnebaum, Ingo B., Schneeweiss, Andreas, Thomssen, Christoph, Untch, Michael   +13 more
core   +1 more source

The effect of darbepoetin alfa on the glomerulus of new-born mice with intrauterine growth restriction [PDF]

Srpski Arhiv za Celokupno Lekarstvo
Introduction/Objective. Intrauterine growth restriction is a condition in which a fetus is not able to achieve its genetic potential for growth. It has been linked with diseases of adulthood, such as hypertension, insulin-independent diabetes mellitus ...
Milojković Milica, Stojanović Vesna, Barišić Nenad   +2 more
doaj   +1 more source

Randomized trial comparing proactive, high-dose versus reactive, low-dose intravenous iron supplementation in hemodialysis (PIVOTAL) : Study design and baseline data [PDF]

, 2018
Background: Intravenous (IV) iron supplementation is a standard maintenance treatment for hemodialysis (HD) patients, but the optimum dosing regimen is unknown.
Anker, Stefan D., Bhandari, Sunil, Farrington, Kenneth, Ford, Ian, Kalra, Philip A., Macdougall, Iain C., McMurray, John J.V., Murray, Heather, Steenkamp, Retha, Tomson, Charles R.V., Wheeler, David C., White, Claire, Winearls, Christopher G.   +12 more
core   +4 more sources

Comparative pharmacoeconomic analysis of the use of erythropoiesis-stimulating drugs for the treatment of anemia in cancer patients

Медицинский совет, 2021
Introduction. Currently, a number of pharmacoeconomic studies describing use of erythropoietin stimulating agent (ESA) in cancer patients with anemia have been published, however, most of the publications on this topic are foreign.
I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova   +2 more
doaj   +1 more source